Bringing CRISPR to the clinic
The rapid rise of CRISPR therapies is changing the face of medicine. IGI is laying the foundation for a new medical specialty that will use genomic disease diagnostics and CRISPR-based treatments as the standard of care for patients with genetic disease: interventional genomics. IGI’s Interventional Genomics Unit (IGU) is creating new tools and workflows to incorporate interventional genomics into clinical practice. Drawing on basic research from UC Berkeley and clinical research from UCSF, the IGI is uniquely positioned to spearhead this approach, with world-leading CRISPR expertise and know-how from basic research through clinical trials. Aligned with the IGI mission, the IGU focuses on areas of urgent, unmet need and/or benefit to historically underserved groups. The IGU has a particular interest in realizing the power of CRISPR to serve individuals with rare genetic disorders.
The IGU consists of three core platforms: 1. the Interventional Genomics Unit for Therapeutic Innovation (INGENUITI); 2. the Assay Development Platform; and 3. the IGI Clinical Lab.
To learn about open positions at the IGI and IGU, see our Careers page.
For any inquiries about the IGU's ongoing work or potential partnerships, please contact Petros Giannikopoulos at firstname.lastname@example.org.